Are you Dr. Klco?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
262 Danny Thomas Pl
Memphis, TN 38105Phone+1 901-595-6807
Summary
- Dr. Jeffery Klco, MD is a board certified pathologist in Memphis, Tennessee. He is currently licensed to practice medicine in Tennessee, California, and Missouri. He is affiliated with St. Jude Children's Research Hospital and is an Instructor at Washington University School of Medicine.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2007 - 2011- Washington University/B-JH/SLCH ConsortiumFellowship, Hematopathology, 2009 - 2010
- Washington University in St. Louis School of MedicineClass of 2007
Certifications & Licensure
TN State Medical License 2014 - 2026
CA State Medical License 2019 - 2025
MO State Medical License 2011 - 2015- American Board of Pathology Pathology - Anatomic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- 541 citationsRole of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaTerrence N. Wong, Giridharan Ramsingh, Andrew L. Young, Christopher A. Miller, Waseem Touma
Nature. 2015-02-26 - 88 citationsEpigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells.David H. Spencer, Margaret A. Young, Tamara Lamprecht, Nichole M. Helton, Robert S. Fulton
Leukemia. 2015-01-20 - 90 citationsAdvances in germline predisposition to acute leukaemias and myeloid neoplasms.Jeffery M. Klco, Charles G. Mullighan
Nature Reviews. Cancer. 2021-02-01
Press Mentions
Targeting Oncogenic Fusions to Combat Pediatric Cancer CellsApril 7th, 2023- St. Jude Tool Targets Cancer-Causing Fusions’ Weak SpotApril 5th, 2023
- Newly Characterized Mutation May Define Novel Pediatric AML SubtypeFebruary 17th, 2022
- Join now to see all
